Objectif
We have identified a novel family of potent small molecule activators of the NLRP3 inflammasome. The goal of this project is to determine the feasibility of developing these new immunostimulators into an attractive commercial proposition. Establishment of technical feasibility will involve identification the most promising modifications of our drug candidates and testing their efficacy in disease models of cancer and immunization. In addition, we will determine commercial feasibility by conducting market research and competition analysis and by engaging potential industry partners.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
ERC-POC - Proof of Concept GrantInstitution d’accueil
UNIVERSITAETSKLINIKUM FREIBURG
Contribution nette de l'UE
€ 150 000,00
Adresse
HUGSTETTER STRASSE 49
79106 Freiburg
Allemagne
79106 Freiburg
Allemagne
Région
Baden-Württemberg
Freiburg
Freiburg im Breisgau, Stadtkreis
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
Aucune donnée